<DOC>
	<DOCNO>NCT03026881</DOCNO>
	<brief_summary>Fluzoparib oral potent , selective PARP-1 PARP-2 inhibitor ; Apatinib oral selective VEGFR inhibitor . This open-label , dose find phase I trial study tolerability best dose Fluzoparib combination apatinib paclitaxel see well three drug work together treatment patient recurrent metastatic gastric cancer progress follow first-line therapy . The safety efficacy fluzoparib combination apatinib paclitaxel explore .</brief_summary>
	<brief_title>A Study Fluzoparib Given Combination With Apatinib Paclitaxel Gastric Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>ECOG performance status 0 1 . Life expectancy 12 week . Histologically cytologically confirm gastric adenocarcinoma ( adenocarcinoma gastroesophageal junction include ) . Recurrent metastatic gastric cancer progress follow first linetherapy . At least one lesion ( measurable and/or nonmeasurable ) accurately assess imaging ( CT/MRI ) baseline Subjects overall good overall general condition . Signed informed consent . Subjects receive previous treatment PARP inhibitor . Subjects receive previous treatment taxanes . More one prior chemotherapy regimen treatment gastric cancer metastatic recurrent set . Less 4 week last clinical trial . Less 2 week last radiotherapy , chemotherapy , surgery , hormone treatment target therapy . Unstable hypertension . Subjects unable swallow , dysfunction gastrointestinal absorption . Subjects brain metastasis . Subjects uncontrolled hypokalemia hypomagnesemia study entry . Subjects know hypersensitivity fluzoparib , apatinib , paclitaxel excipients product . Ongoing infection ( determined investigator ) . History immunodeficiency , include HIVpositive , suffer acquire , congenital immunodeficiency disease , history organ transplantation . Subjects interrupt use drug may cause QT prolongation study . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PARP inhibitor</keyword>
	<keyword>VEGFR inhibitor</keyword>
	<keyword>Combination therapy</keyword>
	<keyword>Gastric cancer</keyword>
</DOC>